Chargement en cours...
Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
Anaplastic lymphoma kinase (ALK) rearrangement lung cancer responds to ALK tyrosine kinase inhibitors. It is known that many cases ultimately acquired resistance to crizotinib. However, a case of primary resistance is rare. We present a case of harboring exon 19 deletion in epidermal growth factor r...
Enregistré dans:
| Publié dans: | Onco Targets Ther |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4712969/ https://ncbi.nlm.nih.gov/pubmed/26811689 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S97100 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|